Every 8-K that Cardiff Oncology, Inc. (CRDF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRDF filings page.
Cardiff Oncology entered into definitive agreements for a registered direct offering of 8,571,429 shares of common stock and accompanying warrants to purchase 8,571,429 shares, at $1.05 per share and warrant, pursuant to its shelf registration statement on Form S-3. Certain officers and directors are also purchasing additional shares and warrants at a higher per-share price.
The warrants have an exercise price of $1.31 per share for outside investors and $1.33 for insiders, become exercisable six months after issuance and after an authorized share increase, and expire five and one-half years after that date. Gross proceeds are approximately $10.05 million, to be used for working capital and general corporate purposes. H.C. Wainwright & Co. acts as exclusive placement agent, earning a 7.0% cash fee and a warrant for 465,157 shares at $1.3125 per share. Cardiff Oncology will seek stockholder approval to increase authorized common shares, committing to file a proxy within 45 days of closing and to hold repeated meetings until approval is obtained or the warrants are no longer outstanding.
Cardiff Oncology, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. A quorum of 41,614,848 common shares was represented in person or by proxy.
Stockholders elected six directors to serve until the 2027 Annual Meeting, including Dr. James O. Armitage, Dr. Rodney Markin, Mani Mohindru, Ph.D., Gary W. Pace, Ph.D., Renee P. Tannenbaum, Pharm.D., and Lâle White. Each nominee received approximately 18.7–18.9 million votes in favor and no votes against, with broker non-votes around 22.3 million.
Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 40,239,508 votes for and 1,070,807 against. An amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable to 15,150,000 was approved with 10,740,460 votes for and 8,063,520 against. In a non-binding advisory vote, compensation of the named executive officers was approved with 17,120,176 votes for and 1,772,185 against.
Cardiff Oncology, Inc. shared updated Phase 2 CRDF-004 data for its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer and outlined plans for a registrational Phase 3 trial. The 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a 72% objective response rate, about 30% higher than standard FOLFIRI/bevacizumab. Median progression-free survival has not yet been reached in key onvansertib arms, while standard-of-care FOLFIRI/bevacizumab showed a median PFS of 12.22 months by investigator assessment. The company completed a successful End-of-Phase 2 FDA meeting and is proposing a ~640-patient pivotal trial with dual primary endpoints of objective response rate and progression-free survival, designed to allow accelerated approval based on response and full approval based on PFS. Safety data indicate no unexpected or new toxicities when onvansertib is added to existing chemotherapy and bevacizumab regimens.
Cardiff Oncology reported first quarter 2026 results and a major clinical and leadership update. The company posted a net loss attributable to common stockholders of $12.4 million, or $0.18 per share, compared with a loss of $13.4 million, or $0.20 per share, a year earlier. Total operating expenses fell to $12.9 million from $14.5 million as research and development spending declined, partly offset by higher selling, general and administrative costs tied to severance and stock‑based compensation. Cash, cash equivalents and short‑term investments totaled $46.1 million as of March 31, 2026, and the company expects this to fund operations into the first quarter of 2027.
Clinically, Cardiff highlighted positive randomized Phase 2 CRDF‑004 data in first‑line RAS‑mutated metastatic colorectal cancer, where the 30 mg onvansertib plus FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2% versus 43.2% across combined standard‑of‑care arms and showed improved progression‑free survival (hazard ratios 0.38 and 0.37, p<0.05) without significant added toxicity. Following a successful End‑of‑Phase 2 FDA meeting, the company selected a 30 mg onvansertib dose with FOLFIRI/bev for a planned Phase 3 registrational trial and plans to share more details by mid‑2026. Cardiff also announced that updated CRDF‑004 data will be presented in a rapid oral session at the 2026 ASCO Annual Meeting and that new preclinical data support combining onvansertib with an antibody‑drug conjugate in HER2‑low breast cancer models. Leadership was strengthened with Mani Mohindru appointed permanent CEO and new CFO and COO hires to support upcoming clinical and regulatory milestones.
Cardiff Oncology is reshaping its leadership team, naming board member and Interim CEO Mani Mohindru, Ph.D., as President and Chief Executive Officer. She receives a base salary of $655,000, a $100,000 bonus and a 55% annual discretionary bonus, plus incentive stock options totaling 800,000 shares with exercise prices of $1.56 and $1.62 per share, vesting over four years.
The company appointed Josh Muntner as Chief Financial Officer effective April 6, 2026, with a $475,000 base salary, 40% annual discretionary bonus and a non-qualified inducement option to purchase 486,650 shares at $1.58 per share, vesting over four years. Ajay Aggarwal, MD, MBA, will become Chief Operating Officer on April 27, 2026, with a $490,000 base salary, 40% annual discretionary bonus and an expected grant of 400,000 stock options.
Cardiff Oncology highlights that there are no special arrangements or family relationships involved in these appointments. The company continues to advance its lead PLK1 inhibitor, onvansertib, in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer and other PLK1-driven tumors.
Cardiff Oncology, Inc. entered into separation agreements on March 27, 2026 with former CEO Dr. Mark Erlander and former CFO James Levine, who had previously stepped down as part of a strategic review.
Dr. Erlander will receive his $635,000 base salary paid over 12 months from the separation date, his 2025 bonus of $122,238, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. He also signed a consulting agreement, and his stock options will continue to vest until June 2026, after which vested options are exercisable for 12 months.
Mr. Levine will receive his $490,000 base salary paid over 12 months, his 2025 bonus of $61,740, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. His vested stock options are exercisable for 12 months after the separation date. Both executives agreed to a general release and confidentiality, and on March 27, 2026, Dr. Erlander also resigned as a director.
Cardiff Oncology furnished a corporate presentation highlighting new Phase 2 data for its oral PLK1 inhibitor onvansertib in first-line RAS‑mutated metastatic colorectal cancer. In the CRDF‑004 trial, onvansertib 30 mg plus FOLFIRI/bevacizumab showed a confirmed objective response rate of 72.2% versus 43.2% for standard chemotherapy regimens and a progression‑free survival hazard ratio of 0.38 versus FOLFIRI/bevacizumab, with median progression‑free survival not yet reached in the onvansertib arms at the January 22, 2026 cut. Safety data indicate no significant added toxicity, supporting selection of the 30 mg dose with FOLFIRI/bevacizumab for a planned registrational program. The company plans an FDA meeting in the first half of 2026 and aims to initiate a Phase 3 trial in the second half of 2026, and reports $58.3 million in cash, cash equivalents, and short‑term investments, funding operations into the first quarter of 2027.
Cardiff Oncology reported full-year 2025 results and highlighted strong Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. In the CRDF-004 trial, the 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2%, versus 43.2% across combined standard-of-care arms, and showed significantly longer progression-free survival (hazard ratio 0.37, p<0.05).
The company plans to advance the 30 mg dose with FOLFIRI/bevacizumab into a planned registrational program, with detailed data and registrational plans expected in the first half of 2026 after FDA discussions. Leadership was realigned for late-stage development, including appointing Mani Mohindru as interim CEO.
Financially, 2025 royalty revenue was $593,000 and total operating expenses were $49.6 million. Net loss attributable to common stockholders was $45.9 million, or $0.69 per share, with weighted-average shares outstanding of 66.8 million. Cash, cash equivalents and short-term investments totaled $58.3 million as of December 31, 2025, which the company believes will fund operations into the first quarter of 2027.
Cardiff Oncology reported major leadership changes and a clinical program update. On January 27, 2026, longtime CEO Dr. Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review. The Board appointed director Dr. Mani Mohindru as interim CEO and promoted Brigitte Lindsay, previously Senior Vice President, Finance, to Chief Accounting Officer.
The company also highlighted a positive update from CRDF-004, a randomized Phase 2 trial of its drug candidate onvansertib combined with standard-of-care regimens in first-line RAS‑mutated metastatic colorectal cancer. Details of the results are provided in an attached press release, which is largely incorporated by reference into this report.
Cardiff Oncology (CRDF) filed an 8-K stating it issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. The press release was furnished as Exhibit 99.1.
The company’s common stock trades on The Nasdaq Stock Market under the symbol CRDF. The report was signed by Chief Executive Officer Mark Erlander on November 6, 2025.
Cardiff Oncology (Nasdaq:CRDF) filed a Form 8-K detailing the 26 June 2025 Annual Meeting vote results.
- All seven director nominees were elected with roughly 20.5-21.2 M votes in favor and no votes against.
- Shareholders ratified BDO USA, P.C. as the independent auditor for FY 2025 (36.3 M for, 1.2 M against, 1.1 M abstain).
- An amendment raising the 2021 Equity Incentive Plan’s share reserve to 12.15 M shares passed (16.9 M for, 5.0 M against).
- The advisory say-on-pay resolution was approved (18.9 M for, 2.6 M against).
No other material business or operational updates were disclosed.